Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for A.P. Møller - Mærsk A/S in connection with the takeover bid for Broström AB
Mandate

Vinge acts for A.P. Møller - Mærsk A/S in connection with the takeover bid for Broström AB

August 27, 2008

Vinge is acting for A.P. Møller - Mærsk A/S in connection with the public offer to the shareholders of Broström AB (publ). The combination of the companies will create the world’s leading product tanker company. Broström is listed on the OMX Nordic Exchange Stockholm. Vinge assists with corporate, capital markets and labour advice. Based on the bid price (SEK 57 per share), Broström is valued to in total SEK 3.62 billion.

The Vinge team includes, inter alia, Göran Nyström (project manager), Pontus Enquist, Mattias Friberg, Jesper Schönbeck, Dain Nevonen, Emil Hedberg and Johan Syrén. Björn Lindskog, Fredrik Dahl och Björn Petersson assist regarding labour law issues.

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025